title: Oxcarbazepine is effective and safe in the treatment of neuropathic pain: pooled analysis of seven clinical studies.
abstract: The results of 7 open-label clinical studies on oxcarbazepine (OXC) in different neuropathic pain conditions, sharing the same protocols, were pooled together in order to evaluate whether the results obtained in the individual trials were confirmed in the pooled analysis of this larger sample, providing more evidence for efficacy and tolerability of OXC in these conditions. Eligible patients (>18 years old) with a diagnosis of neuropathic pain were enrolled in seven open-label trials, consisting of a one-week prospective Screening Phase followed by an eight-week Treatment Phase. Treatment with OXC was initiated at 150 mg/day, and the daily dose was increased by 150 mg/day on a 2-3 day basis to the maximum tolerated dose over four weeks, up to 1800 mg/day. The primary outcome measure was the change in the actual pain rating assessed on the visual analogue scale (VAS) between the end of the Screening Phase and the end of the Treatment Phase. One hundred and thirty-six patients were enrolled in the trials. The mean VAS score dropped from 77.13 at the end of the Screening Phase to 38.41 at the end of the trial for a mean reduction of 50.2%. The percentage of responders (mean VAS score reduction > or = 50%) was 49.2%. OXC was well tolerated, with the most common adverse events consisting of vertigo, tremor, somnolence, hypotension and nausea. The results of this analysis suggest that OXC administered as monotherapy is an efficacious and safe option for the symptomatic treatment of pain associated with neuropathies.
authors.affiliation: Anestesia e Rianimazione I, Azienda Ospedaliera Niguarda Cà Granda, Milan, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Magenta
authors.forename: S
authors.initials: S
authors.lastname: Arghetti
authors.forename: F
authors.initials: F
authors.lastname: Di Palma
authors.forename: S
authors.initials: S
authors.lastname: Jann
authors.forename: M
authors.initials: M
authors.lastname: Sterlicchio
authors.forename: C
authors.initials: C
authors.lastname: Bianconi
authors.forename: V
authors.initials: V
authors.lastname: Galimberti
authors.forename: M
authors.initials: M
authors.lastname: Osio
authors.forename: G
authors.initials: G
authors.lastname: Siciliano
authors.forename: G
authors.initials: G
authors.lastname: Cavallotti
authors.forename: R
authors.initials: R
authors.lastname: Sterzi
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D000078330:Oxcarbazepine; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D012449:Safety
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D000078330:Oxcarbazepine